Insmed (INSM) Receives a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Adam Walsh initiated coverage with a Buy rating on Insmed today and set a price target of $212.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Walsh is a 4-star analyst with an average return of 6.3% and a 45.10% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Insmed, Arcturus Therapeutics, and vTv Therapeutics.
In addition to Stifel Nicolaus, Insmed also received a Buy from RBC Capital’s Leonid Timashev in a report issued on January 21. However, on January 14, Morgan Stanley maintained a Hold rating on Insmed (NASDAQ: INSM).
Based on Insmed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $142.34 million and a GAAP net loss of $370.02 million. In comparison, last year the company earned a revenue of $93.43 million and had a GAAP net loss of $220.52 million
Based on the recent corporate insider activity of 146 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INSM in relation to earlier this year. Earlier this month, Michael Alexander Smith, the CLO of INSM sold 3,158.00 shares for a total of $549,494.32.
Read More on INSM:
Disclaimer & DisclosureReport an Issue
- Insmed initiated with a Buy at Roth Capital
- Insmed price target raised to $200 from $197 at RBC Capital
- Insmed: Strong Brensocatib Launch but Pipeline and Payer Uncertainties Keep Risk‑Reward Balanced at Hold
- Unusually active option classes on open January 9th
- Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating
